HARP News and Press, Harpoon Therapeutics Inc. From 05/06/21

Presented encouraging data at the AACR Annual Meeting on potential therapeutic effects of TriTACs and ProTriTACs Appointed experienced biotech leader A lan Colowick, M.D., to board of directors Clinical data updates for a ...

SOUTH SAN FRANCISCO, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Jerry McMahon, Ph.D., President and Chief Executive Officer, will participate i...

SOUTH SAN FRANCISCO, Calif., April 10, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced the availability of three poster presentations at the American Association for Cance...

An update on the 20 life sciences companies Numenor Capital has profiled so far range from cell therapy companies like SQZ Biotech and Orchard Therapeutics to biologics platforms like Pandion. The best performing investment, over 170% return, so far has been Pandion Therapeutics that ...

Harpoon Therapeutics is a platform immunotherapy company using its TriTAC technology to develop more stable bispecifics to treat cancer. The company has several catalysts for its pipeline of four clinical assets this year that can validate the TriTAC platform. Ultimately, Harpoon ...

SOUTH SAN FRANCISCO, Calif., March 24, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced the appointment of Alan Colowick, M.D., to its board of directors. Dr. Colowick is a...

The following slide deck was published by Harpoon Therapeutics, Inc. in conjunction with their 2020 Q4 earnings call. For further details see: Harpoon Therapeutics, Inc. 2020 Q4 - Results - Earnings Call Presentation

SOUTH SAN FRANCISCO, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced publication of abstracts for three poster presentations at the American Association ...

Harpoon Therapeutics, Inc. (HARP) Q4 2020 Earnings Conference Call March 10, 2021, 04:30 PM ET Company Participants Gerald McMahon - President and CEO Georgia Erbez - CFO Natalie Sacks - Chief Medical Officer Holger Wesche - Chief Scientific Officer Conference Call Participants Jonathan Chang...

Harpoon Therapeutics (HARP): Q4 GAAP EPS of -$0.45 beats by $0.11.Revenue of $7.5M (+236.3% Y/Y) beats by $2.32M.Press Release For further details see: Harpoon Therapeutics EPS beats by $0.11, beats on revenue